SQZ Biotechnologies Gross Profit 2020-2022 | SQZ

SQZ Biotechnologies gross profit from 2020 to 2022. Gross profit can be defined as the profit a company makes after deducting the variable costs directly associated with making and selling its products or providing its services.
SQZ Biotechnologies Annual Gross Profit
(Millions of US $)
2021 $27
2020 $21
2019 $20
SQZ Biotechnologies Quarterly Gross Profit
(Millions of US $)
2022-09-30 $3
2022-06-30 $3
2022-03-31 $3
2021-12-31 $12
2021-09-30 $5
2021-06-30 $5
2021-03-31 $5
2020-12-31 $2
2020-09-30 $6
2020-06-30 $6
2020-03-31 $6
2019-12-31
2019-09-30 $4
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.078B $0.027B
SQZ Biotechnologies Company is a clinical-stage biotechnology company. It develops transformative cell therapies for patients with cancer, infectious diseases and other serious conditions. The company's prime product candidate consist SQZ-PBMC-HPV which is in clinical stage. SQZ Biotechnologies Company is based In Watertown, Massachusetts.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $168.264B 10.27
GSK (GSK) United Kingdom $68.657B 8.61
Bio-Rad Laboratories (BIO.B) United States $12.069B 28.64
QIAGEN (QGEN) Netherlands $11.145B 19.02
Ginkgo Bioworks Holdings (DNA) United States $3.570B 0.00
Myovant Sciences (MYOV) United Kingdom $2.594B 0.00
Arcus Biosciences (RCUS) United States $2.073B 31.12
Biohaven (BHVN) United States $0.982B 0.00
Emergent Biosolutions (EBS) United States $0.579B 4.55
Zymeworks (ZYME) Canada $0.493B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.261B 0.00
Enzo Biochem (ENZ) United States $0.094B 0.00
Gelesis Holdings (GLS) United States $0.028B 0.00
Ambrx Biopharma (AMAM) United States $0.019B 0.00